Ad
related to: difference between first and second line therapy for community acquired pneumonia- Disease Information
Learn About the Risk
Visit Here for More Information.
- FAQs & More
Find Answers to Your Questions
Get More Information Here.
- What is CAPVAXIVE?
Learn About CAPVAXIVE
Visit the Official Patient Site.
- Get CAPVAXIVE
Find a Pharmacy Near You
Access Resources Here.
- Disease Information
Search results
Results From The WOW.Com Content Network
Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person outside of the healthcare system. In contrast, hospital-acquired pneumonia (HAP) is seen in patients who have recently visited a hospital or who live in long-term care facilities.
Hospital-acquired pneumonia, also called nosocomial pneumonia, is pneumonia acquired during or after hospitalization for another illness or procedure with onset at least 72 hrs after admission. The causes, microbiology, treatment and prognosis are different from those of community-acquired pneumonia.
In the United Kingdom, amoxicillin is used as first-line therapy in the vast majority of patients acquiring pneumonia in the community, sometimes with added clarithromycin. In North America , where the "atypical" forms of community-acquired pneumonia are becoming more common, clarithromycin , azithromycin , or fluoroquinolones as single therapy ...
In the UK, treatment before culture results with amoxicillin is recommended as the first line for community-acquired pneumonia, with doxycycline or clarithromycin as alternatives. [69] In North America, amoxicillin, doxycycline, and in some areas a macrolide (such as azithromycin or erythromycin) is the first-line outpatient treatment in adults.
It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal pneumonia is 900,000 annually, with almost 400,000 cases hospitalized and fatalities accounting for 5-7% of these cases. [2]
The carbapenems imipenem and meropenem are recommended by the American Thoracic Society and the Infectious Disease Society of America as one of several first-line therapy options for people with late-onset hospital-acquired or ventilator-associated pneumonia, especially when Pseudomonas, Acinetobacter, or extended spectrum beta-lactamase ...
Hospital acquired pneumonia is the second most common nosocomial infection (after urinary tract infections) and accounts for 15–20% of the total. [ 1 ] [ 2 ] [ 3 ] It is the most common cause of death among nosocomial infections and is the primary cause of death in intensive care units .
Pneumonia occurs in a variety of situations and treatment must vary according to the situation. [11] It is classified as either community or hospital acquired depending on where the patient contracted the infection. It is life-threatening in the elderly or those who are immunocompromised.